US FDA emphasized in a recent warning to consumers that the number of adverse event reports on women with breast-implanted associated anaplastic large cell lymphoma (BIA-ALCL) worldwide has increased by about 246 reports, since last year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?